Efficacy analysis of the new antacid (Vonoprazan) and amoxicillin in the eradication of Helicobacter pylori

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200057709

Enrollment

Unknown

Registered

2022-03-15

Start date

2022-03-01

Completion date

Unknown

Last updated

2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

observation group:Vonolax + Amoxicillin combination regimen

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. 13 C-urea breath test (13 C-UBT) or 14 C-urea breath test (14 C-UBT) positive; 2. The rapid urease test of gastroscopy biopsy was positive; 3. Confirmed by histopathological examination; 4. Monoclonal antibody fecal antigen test positive.

Exclusion criteria

Exclusion criteria: 1. Aged 75 years; 2. Pregnancy, lactation, serious concomitant diseases, malignant tumors, allergic study drugs, severe ulcer bleeding or perforation, history of upper gastrointestinal surgery, previous treatment with H. pylori, PPI or antibiotics within 4 weeks.

Design outcomes

Primary

Measure	Time frame
Helicobacter pylori eradication rate;	—

Countries

China

Contacts

Public ContactHuang Yuanlong

Chengdu Xinhua Hospital

359985006@qq.com+86 15102857874

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026